Endocrine monotherapy of breast cancers is generally hampered by the primary/acquired resistance and adverse sides in clinical settings. Herein, advantaging the multitargeting antitumor effects and normal organ-protecting roles of Chinese herbal medicine, the aim of this study was to investigate the enhanced synergistic efficacy of fulvestrant plus Tan IIA combination therapy in ER-positive breast cancers and to monitor the early response by longitudinal 18F-FES PET/CT imaging. The experimental results showed FUL + Tan IIA combination therapy significantly inhibited tumor growth of ER-positive ZR-75-1 tumor xenografts and exhibited distinct antitumor effects at an earlier time point after treatment than did the monotherapy of FUL or Tan IIA. Moreover, 18F-FES PET/CT imaging competently monitored the early response of FUL + Tan IIA combination therapy. The quantitative 18F-FES %ID/gmax in vivo was further confirmed by and correlated well with ERα expression ex vivo. In conclusion, the synergic effect of FUL + Tan IIA combination therapy to ER-positive breast cancers was verified in the preclinical tumor models and the early treatment response could be monitored by 18F-FES PET/CT.

中文翻译：

---

通过纵向 18F-FES PET/CT 监测氟维司群加丹参酮 IIA 联合疗法对雌激素受体阳性乳腺癌的早期反应。

乳腺癌的内分泌单一疗法通常受到临床环境中原发性/获得性耐药和不利方面的阻碍。在此，利用中草药的多靶向抗肿瘤作用和正常器官保护作用，本研究的目的是研究氟维司群加 Tan IIA 联合治疗对 ER 阳性乳腺癌的协同作用，并监测早期反应。纵向 18F-FES PET/CT 成像。实验结果表明，与 FUL 或 Tan IIA 单药治疗相比，FUL + Tan IIA 联合治疗显着抑制了 ER 阳性 ZR-75-1 肿瘤异种移植物的肿瘤生长，并在治疗后更早的时间点表现出明显的抗肿瘤作用。而且，18F-FES PET/CT 成像能够有效监测 FUL + Tan IIA 联合治疗的早期反应。体内的定量 18F-FES %ID/gmax 得到了体外 ERα 表达的进一步证实并与 ERα 表达密切相关。总之，FUL+Tan IIA联合治疗对ER阳性乳腺癌的协同作用在临床前肿瘤模型中得到验证，早期治疗反应可以通过18F-FES PET/CT监测。